Shanghai FosunPharma’s $1.3 billion acquisition of a majority stake in India’s Gland Pharma is in trouble. It may be rejected by India, not because of the deal itself, but because China and India are in a military stand-off over a small piece of land in the Himalayas, according to a Bloomberg article. The two countries fought a border war over the territory in 1962, and now the border is back in dispute. The Fosun-Gland deal could end up being collateral damage in a larger conflict between the world’s two most populous nations.
Source: ChinaBio Today
